Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity

E-ISSN： 1097-0142|119|16|3076-3083

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.16, 2013-08, pp. : 3076-3083

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multidrug Resistance as a Potential Prognostic Indicator in Acute Myeloid Leukemia with Normal Karyotypes

Acta Haematologica, Vol. 114, Iss. 2, 2005-08 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg^®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 325-334

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E134-E135

John Wiley & Sons Inc

Access to resources Recommend Favorite